Dr Alan Cohen joins MAP Pharmaceuticals
This article was originally published in Scrip
Dr Alan Cohen has joined MAP Pharmaceuticals(US) as vice-president of clinical development and medical affairs, pulmonary. He will oversee development and execution of the company's paediatric asthma clinical programme, including Phase III trials for Unit Dose Budesonide. Dr Cohen has more than 20 years' therapeutic, clinical and medical experience and most recently served as chief medical officer and vice-president of global medical affairs, safety and pharmacovigilance at Jazz Pharmaceuticals.
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.